Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing With Orbimed For Up To $250 Million
Round Type
Grant
SeattleBiotechnologyHealth CareTherapeuticsDescription
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that translates the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it has entered into a non-dilutive royalty financing agreement with OrbiMed for up to $250 million. Proceeds from the agreement will strengthen Adaptive’s balance sheet, which stood at over $450 million in cash and marketable securities at the end of the second quarter of 2022, and provide the Company with additional capital to support its growth trajectory and path to profitability.
Who to call at Adaptive Biotechnologies Corporation, and when
A new round usually means Adaptive Biotechnologies Corporation is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Adaptive Biotechnologies Corporation raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Adaptive Biotechnologies Corporation, from your own LinkedIn network
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Adaptive Biotechnologies Corporation raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Adaptive Biotechnologies Corporation raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.